Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 11/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966069 | 0.97 | OXER1 (0.34) | OXER1LMNAPTGDR2PPARGMAPK8 | |
| SCHEMBL965057 | 0.93 | PTGDR2 (0.34) | OXER1LMNAPTGDR2PPARGMAPK8 | |
| SCHEMBL966630 | 0.92 | PTGDR2 (0.34) | OXER1PTGDR2PPARGMAPK8MAPK9 | |
| SCHEMBL966868 | 0.91 | SLC6A2 (0.35) | OXER1LMNAPTGDR2MAPK8MAPK9 | |
| SCHEMBL967888 | 0.87 | MAPK8 (0.34) | OXER1LMNAPTGDR2PPARGMAPK8 | |
| SCHEMBL964724 | 0.86 | KMO (0.33) | OXER1LMNAPTGDR2PPARGMAPK8 | |
| SCHEMBL962091 | 0.85 | PHGDH (0.34) | LMNAPTGDR2MAPK8 | |
| SCHEMBL964535 | 0.85 | OXER1 (0.33) | OXER1LMNAPTGDR2 | |
| SCHEMBL962752 | 0.85 | PTGDR2 (0.31) | OXER1LMNAPTGDR2PPARG | |
| SCHEMBL964410 | 0.84 | KMO (0.34) | OXER1LMNAPTGDR2MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | OXER1 877/4885LMNA 3461/4885PTGDR2 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.